Interstitium ||| S:0 E:12 ||| NNP
:  ||| S:12 E:14 ||| :
the  ||| S:14 E:18 ||| DT
next  ||| S:18 E:23 ||| JJ
diagnostic  ||| S:23 E:34 ||| JJ
and  ||| S:34 E:38 ||| CC
therapeutic  ||| S:38 E:50 ||| JJ
platform  ||| S:50 E:59 ||| NN
in  ||| S:59 E:62 ||| IN
critical  ||| S:62 E:71 ||| JJ
illness  ||| S:71 E:79 ||| NN
For  ||| S:79 E:83 ||| IN
decades  ||| S:83 E:91 ||| NNS
we  ||| S:91 E:94 ||| PRP
have  ||| S:94 E:99 ||| VBP
been  ||| S:99 E:104 ||| VBN
testing  ||| S:104 E:112 ||| VBG
blood  ||| S:112 E:118 ||| NN
either  ||| S:118 E:125 ||| CC
ex  ||| S:125 E:128 ||| JJ
vivo  ||| S:128 E:133 ||| NN
or  ||| S:133 E:136 ||| CC
else  ||| S:136 E:141 ||| RB
placing  ||| S:141 E:149 ||| VBG
monitors  ||| S:149 E:158 ||| NNS
directly  ||| S:158 E:167 ||| RB
in  ||| S:167 E:170 ||| IN
the  ||| S:170 E:174 ||| DT
bloodstream  ||| S:174 E:186 ||| NN
to  ||| S:186 E:189 ||| TO
see  ||| S:189 E:193 ||| VB
what  ||| S:193 E:198 ||| WP
might  ||| S:198 E:204 ||| MD
be  ||| S:204 E:207 ||| VB
going  ||| S:207 E:213 ||| VBG
on  ||| S:213 E:216 ||| RP
in  ||| S:216 E:219 ||| IN
tissues ||| S:219 E:226 ||| NNS
.  ||| S:226 E:228 ||| .
In  ||| S:228 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
last  ||| S:235 E:240 ||| JJ
20  ||| S:240 E:243 ||| CD
yrs ||| S:243 E:246 ||| NN
,  ||| S:246 E:248 ||| ,
conceptual  ||| S:248 E:259 ||| JJ
and  ||| S:259 E:263 ||| CC
practical  ||| S:263 E:273 ||| JJ
advances  ||| S:273 E:282 ||| NNS
in  ||| S:282 E:285 ||| IN
interstitial  ||| S:285 E:298 ||| JJ
monitoring  ||| S:298 E:309 ||| NN
have  ||| S:309 E:314 ||| VBP
begun  ||| S:314 E:320 ||| VBN
to  ||| S:320 E:323 ||| TO
challenge  ||| S:323 E:333 ||| VB
traditional  ||| S:333 E:345 ||| JJ
approaches ||| S:345 E:355 ||| NNS
.  ||| S:355 E:357 ||| .
In  ||| S:357 E:360 ||| IN
this  ||| S:360 E:365 ||| DT
review  ||| S:365 E:372 ||| NN
we  ||| S:372 E:375 ||| PRP
explore  ||| S:375 E:383 ||| VB
how  ||| S:383 E:387 ||| WRB
interstitial  ||| S:387 E:400 ||| JJ
monitoring  ||| S:400 E:411 ||| NN
might  ||| S:411 E:417 ||| MD
be  ||| S:417 E:420 ||| VB
used  ||| S:420 E:425 ||| VBN
as  ||| S:425 E:428 ||| IN
a  ||| S:428 E:430 ||| DT
platform  ||| S:430 E:439 ||| NN
for  ||| S:439 E:443 ||| IN
future  ||| S:443 E:450 ||| JJ
diagnostics  ||| S:450 E:462 ||| NNS
and  ||| S:462 E:466 ||| CC
therapy  ||| S:466 E:474 ||| NN
in  ||| S:474 E:477 ||| IN
critical  ||| S:477 E:486 ||| JJ
illness ||| S:486 E:493 ||| NN
.  ||| S:493 E:495 ||| .
From  ||| S:495 E:500 ||| IN
a  ||| S:500 E:502 ||| DT
diagnostic  ||| S:502 E:513 ||| JJ
perspective ||| S:513 E:524 ||| NN
,  ||| S:524 E:526 ||| ,
interstitial  ||| S:526 E:539 ||| JJ
analysis  ||| S:539 E:548 ||| NN
has  ||| S:548 E:552 ||| VBZ
been  ||| S:552 E:557 ||| VBN
instructive  ||| S:557 E:569 ||| VBN
about  ||| S:569 E:575 ||| IN
the  ||| S:575 E:579 ||| DT
pathophysiology  ||| S:579 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
critical  ||| S:598 E:607 ||| JJ
illness ||| S:607 E:614 ||| NN
.  ||| S:614 E:616 ||| .
Valuable  ||| S:616 E:625 ||| JJ
insights  ||| S:625 E:634 ||| NNS
have  ||| S:634 E:639 ||| VBP
been  ||| S:639 E:644 ||| VBN
gained  ||| S:644 E:651 ||| VBN
into  ||| S:651 E:656 ||| IN
the  ||| S:656 E:660 ||| DT
pathophysiology  ||| S:660 E:676 ||| NN
of  ||| S:676 E:679 ||| IN
critical  ||| S:679 E:688 ||| JJ
illness ||| S:688 E:695 ||| NN
.  ||| S:695 E:697 ||| .
To  ||| S:697 E:700 ||| TO
this  ||| S:700 E:705 ||| DT
end ||| S:705 E:708 ||| NN
,  ||| S:708 E:710 ||| ,
examples  ||| S:710 E:719 ||| NNS
from  ||| S:719 E:724 ||| IN
the  ||| S:724 E:728 ||| DT
areas  ||| S:728 E:734 ||| NNS
of  ||| S:734 E:737 ||| IN
interstitial  ||| S:737 E:750 ||| JJ
oxygenation  ||| S:750 E:762 ||| NN
and  ||| S:762 E:766 ||| CC
acid  ||| S:766 E:771 ||| JJ
base ||| S:771 E:775 ||| NN
,  ||| S:775 E:777 ||| ,
endocrine  ||| S:777 E:787 ||| JJ
pathophysiology ||| S:787 E:802 ||| NN
,  ||| S:802 E:804 ||| ,
and  ||| S:804 E:808 ||| CC
head  ||| S:808 E:813 ||| NN
injury  ||| S:813 E:820 ||| NN
monitoring  ||| S:820 E:831 ||| NNS
have  ||| S:831 E:836 ||| VBP
been  ||| S:836 E:841 ||| VBN
used ||| S:841 E:845 ||| VBN
.  ||| S:845 E:847 ||| .
From  ||| S:847 E:852 ||| IN
a  ||| S:852 E:854 ||| DT
therapeutic  ||| S:854 E:866 ||| JJ
perspective ||| S:866 E:877 ||| NN
,  ||| S:877 E:879 ||| ,
the  ||| S:879 E:883 ||| DT
main  ||| S:883 E:888 ||| JJ
focus  ||| S:888 E:894 ||| NN
has  ||| S:894 E:898 ||| VBZ
been  ||| S:898 E:903 ||| VBN
on  ||| S:903 E:906 ||| IN
antibiotic  ||| S:906 E:917 ||| JJ
therapy  ||| S:917 E:925 ||| NN
and  ||| S:925 E:929 ||| CC
an  ||| S:929 E:932 ||| DT
improved  ||| S:932 E:941 ||| JJ
understanding  ||| S:941 E:955 ||| NN
of  ||| S:955 E:958 ||| IN
pharmacokinetics  ||| S:958 E:975 ||| NN
and  ||| S:975 E:979 ||| CC
pharmacodynamics  ||| S:979 E:996 ||| NN
in  ||| S:996 E:999 ||| IN
critical  ||| S:999 E:1008 ||| JJ
illness ||| S:1008 E:1015 ||| NN
.  ||| S:1015 E:1017 ||| .
Monitoring  ||| S:1017 E:1028 ||| VBG
of  ||| S:1028 E:1031 ||| IN
the  ||| S:1031 E:1035 ||| DT
interstitium  ||| S:1035 E:1048 ||| NN
is  ||| S:1048 E:1051 ||| VBZ
feasible  ||| S:1051 E:1060 ||| JJ
and  ||| S:1060 E:1064 ||| CC
can  ||| S:1064 E:1068 ||| MD
be  ||| S:1068 E:1071 ||| VB
achieved  ||| S:1071 E:1080 ||| VBN
through  ||| S:1080 E:1088 ||| IN
minimally  ||| S:1088 E:1098 ||| JJ
invasive  ||| S:1098 E:1107 ||| JJ
techniques ||| S:1107 E:1117 ||| NNS
.  ||| S:1117 E:1119 ||| .
It  ||| S:1119 E:1122 ||| PRP
has  ||| S:1122 E:1126 ||| VBZ
improved  ||| S:1126 E:1135 ||| VBN
the  ||| S:1135 E:1139 ||| DT
understanding  ||| S:1139 E:1153 ||| NN
of  ||| S:1153 E:1156 ||| IN
the  ||| S:1156 E:1160 ||| DT
pathophysiology  ||| S:1160 E:1176 ||| NN
of  ||| S:1176 E:1179 ||| IN
critical  ||| S:1179 E:1188 ||| JJ
illness ||| S:1188 E:1195 ||| NN
,  ||| S:1195 E:1197 ||| ,
holds  ||| S:1197 E:1203 ||| VBZ
potential  ||| S:1203 E:1213 ||| JJ
in  ||| S:1213 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
diagnosis  ||| S:1220 E:1230 ||| NN
and  ||| S:1230 E:1234 ||| CC
management  ||| S:1234 E:1245 ||| NN
of  ||| S:1245 E:1248 ||| IN
sepsis ||| S:1248 E:1254 ||| NN
,  ||| S:1254 E:1256 ||| ,
may  ||| S:1256 E:1260 ||| MD
allow  ||| S:1260 E:1266 ||| VB
early  ||| S:1266 E:1272 ||| JJ
prediction  ||| S:1272 E:1283 ||| NN
of  ||| S:1283 E:1286 ||| IN
organ  ||| S:1286 E:1292 ||| JJ
deterioration ||| S:1292 E:1305 ||| NN
,  ||| S:1305 E:1307 ||| ,
and  ||| S:1307 E:1311 ||| CC
finally  ||| S:1311 E:1319 ||| RB
offers  ||| S:1319 E:1326 ||| VBZ
the  ||| S:1326 E:1330 ||| DT
possibility  ||| S:1330 E:1342 ||| NN
of  ||| S:1342 E:1345 ||| IN
reduction  ||| S:1345 E:1355 ||| NN
of  ||| S:1355 E:1358 ||| IN
blood  ||| S:1358 E:1364 ||| NN
testing  ||| S:1364 E:1372 ||| NN
and  ||| S:1372 E:1376 ||| CC
minimizing  ||| S:1376 E:1387 ||| JJ
blood  ||| S:1387 E:1393 ||| NN
loss ||| S:1393 E:1397 ||| NN
.  ||| S:1397 E:1399 ||| .
While  ||| S:1399 E:1405 ||| IN
all  ||| S:1405 E:1409 ||| DT
of  ||| S:1409 E:1412 ||| IN
these  ||| S:1412 E:1418 ||| DT
hold  ||| S:1418 E:1423 ||| NN
promise ||| S:1423 E:1430 ||| NN
,  ||| S:1430 E:1432 ||| ,
randomized  ||| S:1432 E:1443 ||| JJ
trials  ||| S:1443 E:1450 ||| NNS
will  ||| S:1450 E:1455 ||| MD
need  ||| S:1455 E:1460 ||| VB
to  ||| S:1460 E:1463 ||| TO
be  ||| S:1463 E:1466 ||| VB
conducted  ||| S:1466 E:1476 ||| VBN
based  ||| S:1476 E:1482 ||| VBN
on  ||| S:1482 E:1485 ||| IN
interstitial  ||| S:1485 E:1498 ||| JJ
end  ||| S:1498 E:1502 ||| NN
points  ||| S:1502 E:1509 ||| NNS
rather  ||| S:1509 E:1516 ||| RB
than  ||| S:1516 E:1521 ||| IN
plasma  ||| S:1521 E:1528 ||| JJ
end  ||| S:1528 E:1532 ||| NN
points ||| S:1532 E:1538 ||| NNS
.  ||| S:1538 E:1540 ||| .
This  ||| S:1540 E:1545 ||| DT
will  ||| S:1545 E:1550 ||| MD
pave  ||| S:1550 E:1555 ||| VB
the  ||| S:1555 E:1559 ||| DT
way  ||| S:1559 E:1563 ||| NN
for  ||| S:1563 E:1567 ||| IN
a  ||| S:1567 E:1569 ||| DT
more  ||| S:1569 E:1574 ||| RBR
rational  ||| S:1574 E:1583 ||| JJ
approach  ||| S:1583 E:1592 ||| NN
to  ||| S:1592 E:1595 ||| TO
the  ||| S:1595 E:1599 ||| DT
therapy  ||| S:1599 E:1607 ||| NN
of  ||| S:1607 E:1610 ||| IN
critically  ||| S:1610 E:1621 ||| RB
ill  ||| S:1621 E:1625 ||| JJ
patients ||| S:1625 E:1633 ||| NNS
.  ||| S:1633 E:1635 ||| .
